PubRank

Alan J Thompson

Author PubWeight™ 168.80‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011 25.66
2 Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005 24.22
3 A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002 3.74
4 MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol 2007 3.47
5 Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 2005 3.45
6 Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012 3.15
7 Functional-anatomical validation and individual variation of diffusion tractography-based segmentation of the human thalamus. Cereb Cortex 2004 3.03
8 Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 2007 2.53
9 Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002 2.30
10 Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. Ann Neurol 2010 2.24
11 MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 2008 2.08
12 Quality of life measurement after stroke: uses and abuses of the SF-36. Stroke 2002 2.00
13 Motor system activation after subcortical stroke depends on corticospinal system integrity. Brain 2006 1.99
14 Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008 1.91
15 Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004 1.71
16 Effect sizes can be misleading: is it time to change the way we measure change? J Neurol Neurosurg Psychiatry 2010 1.70
17 New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann Neurol 2003 1.66
18 Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003 1.62
19 The evolution of prefrontal inputs to the cortico-pontine system: diffusion imaging evidence from Macaque monkeys and humans. Cereb Cortex 2005 1.61
20 Patient-based outcomes of cervical dystonia: a review of rating scales. Mov Disord 2004 1.59
21 Disability, atrophy and cortical reorganization following spinal cord injury. Brain 2011 1.58
22 Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002 1.57
23 Exploring rating scale responsiveness: does the total score reflect the sum of its parts? Neurology 2004 1.54
24 Optic nerve diffusion tensor imaging in optic neuritis. Neuroimage 2005 1.54
25 Characterizing function-structure relationships in the human visual system with functional MRI and diffusion tensor imaging. Neuroimage 2004 1.52
26 The therapeutic potential of cannabis. Lancet Neurol 2003 1.49
27 Functional anatomy of interhemispheric cortical connections in the human brain. J Anat 2006 1.45
28 Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: evidence that axonal loss is a substrate of MRI-detected atrophy. Neuroimage 2006 1.41
29 The relationship between brain activity and peak grip force is modulated by corticospinal system integrity after subcortical stroke. Eur J Neurosci 2007 1.34
30 A serial MRI study following optic nerve mean area in acute optic neuritis. Brain 2004 1.32
31 Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. J Neurol 2009 1.29
32 Optic radiation changes after optic neuritis detected by tractography-based group mapping. Hum Brain Mapp 2005 1.29
33 The influence of time after stroke on brain activations during a motor task. Ann Neurol 2004 1.27
34 A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging--evidence of Wallerian degeneration. J Neurol 2003 1.26
35 Two-dimensional population map of cortical connections in the human internal capsule. J Magn Reson Imaging 2007 1.24
36 Selective magnetization transfer ratio decrease in the visual cortex following optic neuritis. Brain 2006 1.23
37 Exploring the relationship between white matter and gray matter damage in early primary progressive multiple sclerosis: an in vivo study with TBSS and VBM. Hum Brain Mapp 2009 1.22
38 The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology. J Magn Reson Imaging 2002 1.16
39 Investigation of white matter pathology in ALS and PLS using tract-based spatial statistics. Hum Brain Mapp 2009 1.11
40 The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials 2011 1.09
41 Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study. Arch Neurol 2006 1.07
42 Localization of grey matter atrophy in early RRMS : A longitudinal study. J Neurol 2006 1.06
43 Corticomotor representation to a human forearm muscle changes following cervical spinal cord injury. Eur J Neurosci 2011 1.06
44 Adaptive cortical plasticity in higher visual areas after acute optic neuritis. Ann Neurol 2005 1.05
45 Treatment of cognitive impairment in multiple sclerosis: position paper. J Neurol 2012 1.04
46 Functional significance of the ipsilateral hemisphere during movement of the affected hand after stroke. Exp Neurol 2004 1.03
47 Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain 2005 1.02
48 Longitudinal changes in cerebral response to proprioceptive input in individual patients after stroke: an FMRI study. Neurorehabil Neural Repair 2006 1.01
49 Normal-appearing brain t1 relaxation time predicts disability in early primary progressive multiple sclerosis. Arch Neurol 2007 1.00
50 Method for simultaneous voxel-based morphometry of the brain and cervical spinal cord area measurements using 3D-MDEFT. J Magn Reson Imaging 2010 0.99
51 Visual recovery following acute optic neuritis--a clinical, electrophysiological and magnetic resonance imaging study. J Neurol 2004 0.99
52 Degeneration of the injured cervical cord is associated with remote changes in corticospinal tract integrity and upper limb impairment. PLoS One 2012 0.98
53 Upper cervical cord area in early relapsing-remitting multiple sclerosis: cross-sectional study of factors influencing cord size. J Magn Reson Imaging 2006 0.98
54 Axonal integrity predicts cortical reorganisation following cervical injury. J Neurol Neurosurg Psychiatry 2012 0.97
55 Assessing neuronal metabolism in vivo by modeling imaging measures. J Neurosci 2010 0.97
56 Magnetization transfer ratio in gray matter: a potential surrogate marker for progression in early primary progressive multiple sclerosis. Arch Neurol 2008 0.96
57 What sample sizes for reliability and validity studies in neurology? J Neurol 2012 0.95
58 Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosis. Mult Scler 2010 0.94
59 Factors influencing work retention for people with multiple sclerosis: cross-sectional studies using qualitative and quantitative methods. J Neurol 2005 0.94
60 The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis. J Neurol 2002 0.93
61 Effects of a short outpatient rehabilitation treatment on disability of multiple sclerosis patients--a randomised controlled trial. J Neurol 2003 0.93
62 Neuroplasticity and functional recovery in multiple sclerosis. Nat Rev Neurol 2012 0.93
63 Conversion efficiency of skutterudite-based thermoelectric modules. Phys Chem Chem Phys 2014 0.92
64 Atopic myelitis in a European woman residing in Japan. J Neurol Neurosurg Psychiatry 2010 0.92
65 Abnormal connectivity of the sensorimotor network in patients with MS: a multicenter fMRI study. Hum Brain Mapp 2009 0.91
66 Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis. J Magn Reson Imaging 2003 0.90
67 Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis? J Neurol 2003 0.90
68 Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. Neuroimage 2004 0.90
69 Application of a B-spline active surface technique to the measurement of cervical cord volume in multiple sclerosis from three-dimensional MR images. J Magn Reson Imaging 2003 0.89
70 Changes in auditory feedback connections determine the severity of speech processing deficits after stroke. J Neurosci 2012 0.88
71 Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis. Clin Neurol Neurosurg 2005 0.87
72 The cervical dystonia impact profile (CDIP-58): can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria? Health Qual Life Outcomes 2008 0.87
73 Specificity of Barkhof criteria in predicting conversion to multiple sclerosis when applied to clinically isolated brainstem syndromes. Arch Neurol 2004 0.87
74 The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosis. J Neurol 2005 0.86
75 Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy. J Neurol 2002 0.85
76 Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR. J Neurol 2002 0.85
77 Metabolic changes in the spinal cord after brachial plexus root re-implantation. Neurorehabil Neural Repair 2012 0.84
78 Multiple sclerosis--a global disorder and still poorly managed. Lancet Neurol 2008 0.84
79 Primary progressive multiple sclerosis : current and future treatment options. CNS Drugs 2005 0.84
80 Refinement and validation of the Parental Illness Impact Scale. Parkinsonism Relat Disord 2009 0.83
81 The impact of inpatient neurorehabilitation on psychological well-being on discharge and at 3 month follow-up. J Neurol 2005 0.83
82 Scanning laser polarimetry quantification of retinal nerve fiber layer thinning following optic neuritis. J Neuroophthalmol 2010 0.82
83 A novel approach with "skeletonised MTR" measures tract-specific microstructural changes in early primary-progressive MS. Hum Brain Mapp 2013 0.82
84 Low myo-inositol indicating astrocytic damage in a case series of neuromyelitis optica. Ann Neurol 2013 0.81
85 Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Mult Scler 2008 0.81
86 Spatial variability and changes of metabolite concentrations in the cortico-spinal tract in multiple sclerosis using coronal CSI. Hum Brain Mapp 2012 0.80
87 Integrated care pathways: disease-specific or process-specific? Clin Med 2004 0.80
88 TI-relaxation time changes over five years in relapsing-remitting multiple sclerosis. Mult Scler 2010 0.79
89 Interferon beta-1a in primary progressive multiple sclerosis. J Neurol Sci 2003 0.79
90 Corpus callosum damage predicts disability progression and cognitive dysfunction in primary-progressive MS after five years. Hum Brain Mapp 2012 0.79
91 Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists. FASEB J 2013 0.79
92 Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years. BMC Neurol 2008 0.79
93 Evidence-based guidelines for using the Short Form 36 in cervical dystonia. Mov Disord 2007 0.78
94 Overview of London trial of intramuscular interferon-beta Ia in primary-progressive multiple sclerosis. Mult Scler 2004 0.77
95 A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS). Health Qual Life Outcomes 2011 0.77
96 Socio-demographic variables are limited predictors of health status in multiple sclerosis. J Neurol 2003 0.77
97 Patient dissatisfaction: insights into the rehabilitation process. J Neurol 2004 0.77
98 A longitudinal functional MRI study of non-arteritic anterior ischaemic optic neuropathy patients. J Neurol Neurosurg Psychiatry 2011 0.77
99 Asymmetric hemispheric representation of periictal heart rate modulation is individually lateralised. Epileptic Disord 2011 0.76
100 Dissecting the familial risk of multiple sclerosis. Ann Neurol 2011 0.76
101 Is multiple sclerosis still a clinical diagnosis? Neurology 2003 0.76
102 The size of the treatment effect: do patients and proxies agree? BMC Neurol 2009 0.75
103 Cannabinoids in MS: potentially useful but not just yet! Neurology 2002 0.75
104 Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a. J Negat Results Biomed 2004 0.75
105 Magnetic resonance imaging in primary progressive multiple sclerosis. J Rehabil Res Dev 2002 0.75
106 Developing clinical outcome measures in multiple sclerosis: an evolving process. Mult Scler 2002 0.75
107 Rehabilitation of the cancer patient: experience in a neurological unit. Neurorehabil Neural Repair 2004 0.75
108 Early accurate diagnosis crucial in multiple sclerosis. Practitioner 2015 0.75
109 Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a. J Neurol 2003 0.75
110 Promises, promises... Ann Neurol 2007 0.75
111 Removal of access to alemtuzumab for patients with aggressive multiple sclerosis. BMJ 2013 0.75
112 Diagnosing and managing multiple sclerosis. Practitioner 2009 0.75
113 GPs have pivotal role in managing MS. Practitioner 2007 0.75
114 Professor Ian McDonald (1933 2006). Mult Scler 2007 0.75